Liquid biopsy as a new era in endometrial cancer

Abstract

Endometrial cancer (EC) is one of the most frequent invasive cancers of the female genital tract, and despite the rising incidence of EC worldwide and the poor overall survival of patients, no viable blood-based biomarker exists to detect and track EC recurrence during routine follow-up. Identification of new genetic targets and biomarkers linked to enhanced recurrence risk and medication response is a primary clinical issue in the treatment of advanced endometrial cancer. In this regard, liquid biopsy has become a breakthrough in human cancers. A liquid biopsy blood test has the advantage of being more sensitive than traditional imaging and is a minimally invasive complement to needle or excision biopsies of tissue. Here in this article, we discussed the advances and limitations of liquid biopsy. The detection of biomarkers and variations in liquid biopsy may help the diagnostic process of endometrial cancer cases.